Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lipitor Generics Problem Illustrates Need For Hatch-Waxman Reform, Academics Say

This article was originally published in The Pink Sheet Daily

Executive Summary

Even with revised use-it-or-lose it provisions, exclusivity parking is still prevalent and won't be prevented by banning "pay-for-delay" settlements, David Balto and Michael Carrier argue.
Advertisement

Related Content

Brand-Generic "Pay-For-Delay" Settlements Jump 63% In FY 2010
Brand-Generic "Pay-For-Delay" Settlements Jump 63% In FY 2010
Lipitor Generics: FDA Says Mylan Has No Standing To Sue (Until June 28?)
Lipitor Generic Bottleneck Needs To Be Cleared "Now," Senators Tells FDA
Lipitor Generic Bottleneck Needs To Be Cleared "Now," Senators Tells FDA
Teva Settlements Stick To Date of Entry Even As Legislative Debate Continues

Topics

Advertisement
UsernamePublicRestriction

Register

PS072154

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel